Mazdutide TFA  (Synonyms: IBI-362 TFA; LY-3305677 TFA; OXM-3 TFA)

Mazdutide (IBI-362; LY-3305677) TFA is a long-acting synthetic oxyntomodulin analog. Mazdutide is also a co-agonist of glucagon-like peptide (GLP-1R) and glucagon receptor (GCGR). Mazdutide TFA binds human and mouse GCGR (K_i: 17.7 nM and 15.9 nM, respectively) and GLP-1R (K_i: 28.6 nM and 25.1 nM, respectively) and stimulates insulin secretion from mouse islets (EC₅₀: 5.2 nM). Mazdutide TFA is used in studies of obesity and type 2 diabetes (T2D)^[1][2][3].

Mazdutide (15, 30 nmol/kg; sc; single dose) TFA significantly reduces body weight and physical intake in diabetic mice with diet-induced obesity (DIO)^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

4563.06 (free base)

C₂₁₀H₃₂₂N₄₆O₆₇.xC₂HF₃O₂

His-{Aib}-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Glu-Lys-Lys-Ala-Lys-{AEEA-AEEA-γGlu-Nonadecanoic acid}-Glu-Phe-Val-Glu-Trp-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-NH2

H-{Aib}-QGTFTSDYSKYLDEKKAK-{AEEA-AEEA-γGlu-Nonadecanoic acid}-EFVEWLLEGGPSSG-NH2

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Chen T, et al. The Design and Optimization of Monomeric Multitarget Peptides for the Treatment of Multifactorial Diseases. J Med Chem. 2022 Mar 10;65(5):3685-3705.  [Content Brief]

  [2]. Jiang H, et al. A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes. Nat Commun. 2022 Jun 24;13(1):3613.  [Content Brief]

  [3]. Chen Y, Mezo A, Coskun T, et al. 682-P: novel dual glucagon and glucagon-like peptide-1 receptor agonist LY3305677 improves glucose control, reduces body weight, and increases energy expenditure in mice[J]. Diabetes, 2021, 70(Supplement_1).